Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 1;77(3):942-948.
doi: 10.1002/hep.32642. Epub 2023 Feb 17.

Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality

Laurens A van Kleef  1 , Robert J de Knegt, Willem Pieter Brouwer
Affiliations

Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality

Laurens A van Kleef et al. Hepatology. .

Abstract

Background and aims: MAFLD often cooccurs with excessive alcohol consumption, while its prognostic value in this group remains unclear. We aimed to study the mortality risk of MAFLD in relation to excessive alcohol consumption and its potential interactions.

Approach and results: We analyzed persons 25-74 years old enrolled in the National Health and Nutrition Examination Survey III cohort with available steatosis and alcohol data. Participants with viral hepatitis, body mass index < 18.5, and missing data on age or follow-up were excluded, leaving 12,656 participants for analysis with a median follow-up of 22.9 [20.9-24.8] years. MAFLD was defined as steatosis on ultrasound in the presence of metabolic dysfunction. Daily alcohol intake of ≥10 g in females and ≥20 g in males was considered excessive alcohol consumption. We quantified mortality risk with multivariate Cox regression for MAFLD and excessive alcohol consumption. Models were adjusted for age, age squared, sex, race, marital status, education, and smoking. MAFLD was present in 31% and excessive alcohol consumption in 13% and were both independently and simultaneously associated with increased mortality risk in fully adjusted models (adjusted HR [aHR], 1.21; 95% CI, 1.13-1.30 and aHR, 1.14; 95% CI, 1.04-1.26, respectively). Similarly, MAFLD was associated with increased mortality risk in participants with and without excessive alcohol consumption. Participants with both MAFLD and excessive alcohol consumption (4.0%) expressed the highest mortality risk (aHR, 1.47; 95% CI, 1.28-1.71). Results were consistent using the initial 10 years of follow-up, a stringent definition of excessive alcohol, and propensity score weighting.

Conclusions: MAFLD increases mortality risk independent of excessive alcohol consumption. This underscores the importance of MAFLD, even in patients with excessive alcohol consumption.

PubMed Disclaimer

Conflict of interest statement

Robert J. de Knegt advises for and received grants from AbbVie and Gilead. He is on the speakers’ bureau for Echosens. He received grants from GSK.

Figures

None
Graphical abstract
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero‐Gomez M, et al. . A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–9. - PubMed
    1. Van Kleef L, Ayada I, Alferink L, Pan Q, de Knegt RJ. Metabolic dysfunction associated fatty liver disease improves detection of high liver stiffness: the Rotterdam Study. Hepatology. 2021;75:419–29. - PMC - PubMed
    1. Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. . Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40:2082–9. - PubMed
    1. Wong VW, Wong GL, Woo J, Abrigo JM, Chan CK, Shu SS, et al. . Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021;19:2161–71.e5. - PubMed
    1. van Kleef LA, HSJ C, Brouwer WP, Hansen BE, Patel K, de Man RA, et al. . Metabolic dysfunction‐associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 2021;3:100350. - PMC - PubMed

Publication types